Efficacy of Albumin-Bound Paclitaxel and Carboplatin as a First-Line Treatment for Advanced Lung Squamous Cell Carcinoma
Objective To observe the clinical effects and adverse effects of albumin-bound paclitaxel and carboplatin as a first-line treatment for advanced lung squamous cell carcinoma.Methods A total of 86 patients with advanced lung squamous cell carcinoma(stage ⅢB/Ⅳ)treated in the department of respiratory and critical care medicine,Zaozhuang Municipal Hospital from December 2020 to December 2022 were selected as the study subjects.Patients were divided into experimental and control groups according to the random number table method.The experimental group received albumin-combined paclitaxel with carboplatin(NC experimental group,sample number of 40 patients),and the control group received gemcitabine and carboplatin(GC control group,46 samples).To compare the clinical efficacy and adverse effects.Results The comparison between the objective response rate and the disease control rate.The patients who were treated with nab-Paclitaxel plus carboplatin(group NC)had an objective response rate of 40%(16/40).The disease control rates was 72.5%(29/40).Meanwhile,the patients who were treated with gemcitabine plus carboplatin(group GC)had an objective response rate of 26%(12/46);.The disease control rates(DCR)was 65.2%(30/46).Our results suggested that ORR improved 14%in group NC,compared to that in group GC.However,there was no significant difference in short-term efficacy between two groups(P>0.05).The median progression-free survival(PFS)was 5.10 months in group NC and 4.60 months in group GC.Progression-free survival in two groups showed no significant difference(P>0.05).All the two groups showed myelosuppression,nausea/vomiting,diarrhea,toxicity of peripheral nerve,myalgia/arthralgia,etc.Among them,the incidence of thrombocytopenia in NC group was lower than that of GC group,and the incidence of peripheral neurotoxicity in NC group was higher than that of GC group,with statistically significant differences(P<0.05).Comparison of other adverse effects,no significant difference(P>0.05).Conclusion Administering a combination of albumin-paclitaxel and carboplatin as an initial therapy for individuals with advanced lung squamous cell carcinoma has been proven both safe and efficacious,with tolerable side effects.Additional studies involving more participants are recommended to substantiate these findings.
万方数据
维普
